通过调节标准NF-κB通路,NLRP12减轻了臭氧诱导的肺炎
Mengyuan Li1, Yuan Xue1, Xinyi Miao1
1Department of Toxicology, College of Public Health, Zhengzhou University, Zhengzhou, Henan Province, China.
Ecotoxicology and environmental safety
|August 2, 2023
概括
通过抑制NF-κB通路,NLRP12可以防止臭氧引起的气道过敏和肺炎. 这一发现为与臭氧相关的呼吸道疾病提供了新的治疗点.
科学领域:
- 环境健康 环境健康
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- 臭氧 (O3) 是一个主要的城市空气污染物,与呼吸系统疾病有关.
- 已知暴露于臭氧会导致气道过敏反应 (AHR) 和肺炎.
- 在臭氧诱导的肺炎中,抑制性先天性免疫受体 (如NLRP12) 的作用尚不清楚.
研究的目的:
- 研究NLRP12在臭氧诱导的AHR和肺炎中的保护作用.
- 为了确定NLRP12是否通过抑制正规NF-κB通路来发挥其作用.
主要方法:
- 小鼠接触到不同度的臭氧 (O3) 或过空气 (FA).
- 测量了气道阻力,炎症细胞计数,蛋白质水平和支气管洗液 (BALF) 中的细胞因子度.
- 分析了肺NLRP12表达和NF-κB通路激活标记物.
- 通过对腺病毒进行内注射来实现NLRP12的过度表达.
主要成果:
- 在BALF中,臭氧暴露剂量依赖增加了AHR,炎症细胞,蛋白质和细胞因子.
- 臭氧暴露降低了肺NLRP12水平,并增加了正规NF-κB通路 (酸化IRAK1,p65,IκBα) 的激活.
- 过度表达NLRP12减弱了臭氧诱导的AHR和肺炎,并抑制了NF-κB激活.
结论:
- NLRP12在减轻臭氧诱导的AHR和肺炎方面起着保护作用.
- NLRP12可能通过调节正规NF-κB通路来发挥其保护作用.
- NLRP12代表了预防和治疗臭氧暴露引起的肺部疾病的潜在治疗标.
相关概念视频
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Co-activators and Co-repressors
7.4K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.4K
Antiasthma Drugs: Leukotriene Modifiers
361
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
361
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Drugs Used in Lower Respiratory Disorders: Overview
489
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
489
Regulation of the Unfolded Protein Response
2.5K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.5K


